These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 21835789)
1. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. Eggink D; Bontjer I; Langedijk JP; Berkhout B; Sanders RW J Virol; 2011 Oct; 85(20):10785-97. PubMed ID: 21835789 [TBL] [Abstract][Full Text] [Related]
2. Selection of T1249-resistant human immunodeficiency virus type 1 variants. Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391 [TBL] [Abstract][Full Text] [Related]
3. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. Eggink D; Langedijk JP; Bonvin AM; Deng Y; Lu M; Berkhout B; Sanders RW J Biol Chem; 2009 Sep; 284(39):26941-50. PubMed ID: 19617355 [TBL] [Abstract][Full Text] [Related]
4. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket. Su Y; Chong H; Qiu Z; Xiong S; He Y J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278 [TBL] [Abstract][Full Text] [Related]
5. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains. Pan C; Cai L; Lu H; Qi Z; Jiang S J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996 [TBL] [Abstract][Full Text] [Related]
6. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry. Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor. Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981 [TBL] [Abstract][Full Text] [Related]
8. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses. Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor. Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334 [TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358 [TBL] [Abstract][Full Text] [Related]
11. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41. Wang W; De Feo CJ; Zhuang M; Vassell R; Weiss CD J Virol; 2011 Dec; 85(24):12929-38. PubMed ID: 21994458 [TBL] [Abstract][Full Text] [Related]
12. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952 [TBL] [Abstract][Full Text] [Related]
13. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120. Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362 [TBL] [Abstract][Full Text] [Related]
14. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket. Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597 [TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. Chinnadurai R; Rajan D; Münch J; Kirchhoff F J Virol; 2007 Jun; 81(12):6563-72. PubMed ID: 17428857 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851 [TBL] [Abstract][Full Text] [Related]
18. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion. He Y Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277 [TBL] [Abstract][Full Text] [Related]
19. Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. Yu X; Lu L; Cai L; Tong P; Tan S; Zou P; Meng F; Chen YH; Jiang S J Virol; 2012 Jan; 86(1):589-93. PubMed ID: 22013063 [TBL] [Abstract][Full Text] [Related]
20. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. Hermann FG; Egerer L; Brauer F; Gerum C; Schwalbe H; Dietrich U; von Laer D J Virol; 2009 May; 83(10):4844-53. PubMed ID: 19279116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]